|
Real-time Estimate
Cboe BZX
13:15:30 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 4.190 USD | +1.95% |
|
+12.84% | +76.91% |
| 10-14 | Rezolute Says Phase 3 upLIFT Study Fully Enrolled, Topline Data Due Mid-December | MT |
| 10-14 | Rezolute, Inc. Completes Enrollment In Phase 3 upLIFT Study Of Ersodetug In Tumor Hyperinsulinism | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 431M | - | - | - | - | - |
| 63.48B | |||||
| 54.55B | |||||
| 53.59B | |||||
| 44.75B | |||||
| 41.62B |
- Stock Market
- Stocks
- RZLT Stock
- Charts Rezolute, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
